In vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesunate, artemether, or OZ78

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4596-4604

  Duthaler, Urs ^a,b   Smith, Thomas A ^a,b   Keiser, Jennifer ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; ARTEMETHER; ARTESUNATE; OZ 78; TRICLABENDAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; FASCIOLA HEPATICA; FASCIOLIASIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; WORM;

ADAMANTANE; ANIMALS; ANTHELMINTICS; ARTEMISININS; BENZIMIDAZOLES; FASCIOLA HEPATICA; FASCIOLIASIS; FEMALE; RATS; RATS, WISTAR;

EID: 78049250368     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00828-10     Document Type: Article

References (39)

1. Bennett, J. L., and P. Kohler. 1987. Fasciola hepatica: action in vitro of triclabendazole on immature and adult stages. Exp. Parasitol. 63:49-57.
2. Boray, J. C., P. D. Crowfoot, M. B. Strong, J. R. Allison, M. Schellenbaum, M. Von Orelli, and G. Sarasin. 1983. Treatment of immature and mature Fasciola hepatica infections in sheep with triclabendazole. Vet. Rec. 113:315-317.
3. Chou, T. C. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58:621-681.
4. Cringoli, G., L. Rinaldi, M. P. Maurelli, and J. Utzinger. 2010. FLOTAC: new multivalent techniques for qualitative and quantitative copromicroscopic diagnosis of parasites in animals and humans. Nat. Protoc. 5:503-515.
5. DeFronzo, R. A. 2010. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am. J. Med. 123:S38-S48.
6. Diab, T. M., H. H. Mansour, and S. S. Mahmoud. 2010. Fasciola gigantica: parasitological and scanning electron microscopy study of the in vitro effects of ivermectin and/or artemether. Exp. Parasitol. 124:279-284.
7. Duthaler, U., L. Rinaldi, M. P. Maurelli, M. Vargas, J. Utzinger, G. Cringoli, and J. Keiser. 2010. Fasciola hepatica: comparison of the sedimentation and FLOTAC techniques for the detection and quantification of faecal egg counts in rats. Exp. Parasitol. 126:161-166.
8. Edwards, G., and S. Krishna. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections. Eur. J. Clin. Microbiol. Infect. Dis. 23:233-242.
9. Efferth, T., and B. Kaina. 2010. Toxicity of the antimalarial artemisinin and its dervatives. Crit. Rev. Toxicol. 40:405-421.
10. Fairweather, I. 2009. Triclabendazole progress report, 2005-2009: an advancement of learning? J. Helminthol. 83:139-150.
11. Fairweather, I., and J. C. Boray. 1999. Fasciolicides: efficacy, actions, resistance and its management. Vet. J. 158:81-112.
12. Gupta, A. K., S. Arshad, and N. R. Poulter. 2010. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55:399-407.
13. Keiser, J. 2010. In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology 137:589-603.
14. Keiser, J., D. Engels, G. Buscher, and J. Utzinger. 2005. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin. Investig. Drugs 14:1513-1526.
15. Keiser, J., M. S. Gruyer, N. Perrottet, B. Zanolari, T. Mercier, and L. Decosterd. 2009. Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica. J. Antimicrob. Chemother. 63:543-549.
16. Keiser, J., C. Kirchhofer, M. Haschke, J. Huwyler, Y. Dong, J. L. Vennerstrom, K. Vanhoff, R. Kaminsky, and N. Malikides. 2010. Efficacy, safety and pharmacokinetics of 1,2,4-trioxolane OZ78 against an experimental infection with Fasciola hepatica in sheep. Vet. Parasitol. doi: 10.1016/j.vetpar.2010.06. 031.
17. Keiser, J., and G. Morson. 2008. Fasciola hepatica: tegumental alterations in adult flukes following in vitro and in vivo administration of artesunate and artemether. Exp. Parasitol. 118:228-237.
18. Keiser, J., L. Rinaldi, V. Veneziano, L. Mezzino, M. Tanner, J. Utzinger, and G. Cringoli. 2008. Efficacy and safety of artemether against a natural Fasciola hepatica infection in sheep. Parasitol. Res. 103:517-522.
19. Keiser, J., X. Shu-Hua, M. Tanner, and J. Utzinger. 2006. Artesunate and artemether are effective fasciolicides in the rat model and in vitro. J. Antimicrob. Chemother. 57:1139-1145.
20. Keiser, J., and J. Utzinger. 2009. Food-borne trematodiases. Clin. Microbiol. Rev. 22:466-483.
21. Keiser, J., J. Utzinger, M. Tanner, Y. Dong, and J. L. Vennerstrom. 2006. The synthetic peroxide OZ78 is effective against Echinostoma caproni and Fasciola hepatica. J. Antimicrob. Chemother. 58:1193-1197.
22. Keiser, J., J. Utzinger, J. L. Vennerstrom, Y. Dong, G. Brennan, and I. Fairweather. 2007. Activity of artemether and OZ78 against triclabendazole- resistant Fasciola hepatica. Trans. R. Soc. Trop. Med. Hyg. 101:1219-1222.
23. Keiser, J., V. Veneziano, L. Rinaldi, L. Mezzino, U. Duthaler, and G. Cringoli. 2010. Anthelmintic activity of artesunate against Fasciola hepatica in naturally infected sheep. Res. Vet. Sci. 88:107-110.
24. Keiser, J., S. H. Xiao, T. A. Smith, and J. Utzinger. 2009. Combination chemotherapy against Clonorchis sinensis: experiments with artemether, artesunate, OZ78, praziquantel, and tribendimidine in a rat model. Antimicrob. Agents Chemother. 53:3770-3776.
25. Manneck, T., O. Braissant, W. Ellis, and J. Keiser. 2010. Schistosoma mansoni: antischistosomal activity of the four optical isomers and the two racemates of mefloquine on schistosomula and adult worms in vitro and in vivo. Exp. Parasitol. doi:10.1016/j.exppara.2010.08.011.
26. Mas-Coma, S., M. D. Bargues, and M. A. Valero. 2005. Fascioliasis and other plant-borne trematode zoonoses. Int. J. Parasitol. 35:1255-1278.
27. McManus, D. P., and J. P. Dalton. 2006. Vaccines against the zoonotic trematodes Schistosoma japonicum, Fasciola hepatica and Fasciola gigantica. Parasitology 133(Suppl.):S43-S61.
28. Meaney, M., J. Allister, B. McKinstry, K. McLaughlin, G. P. Brennan, A. B. Forbes, and I. Fairweather. 2006. Fasciola hepatica: morphological effects of a combination of triclabendazole and clorsulon against mature fluke. Parasitol. Res. 99:609-621.
29. O'Neill, J. F., R. C. Johnston, L. Halferty, G. P. Brennan, J. Keiser, and I. Fairweather. 2009. Adult triclabendazole-resistant Fasciola hepatica: morphological changes in the tegument and gut following in vivo treatment with artemether in the rat model. J. Helminthol. 83:151-163.
30. Raffa, R. B., R. Clark-Vetri, R. J. Tallarida, and A. I. Wertheimer. 2003. Combination strategies for pain management. Expert Opin. Pharmacother. 4:1697-1708.
31. Robinson, M. W., and J. P. Dalton. 2009. Zoonotic helminth infections with particular emphasis on fasciolosis and other trematodiases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364:2763-2776.
32. Smeal, M. G., and C. A. Hall. 1983. The activity of triclabendazole against immature and adult Fasciola hepatica infections in sheep. Aust. Vet. J. 60:329-331.
33. Stitt, A. W., and I. Fairweather. 1996. Fasciola hepatica: disruption of the vitelline cells in vitro by the sulphoxide metabolite of triclabendazole. Parasitol. Res. 82:333-339.
34. Stitt, A. W., and I. Fairweather. 1992. Spermatogenesis in Fasciola hepatica - an ultrastructural comparison of the effects of the anthelmintic, triclabendazole (fasinex) and the microtubule inhibitor, tubulozole. Invertebr. Reprod. Dev. 22:139-150.
35. Toner, E., F. McConvery, G. P. Brennan, M. Meaney, and I. Fairweather. 2009. A scanning electron microscope study on the route of entry of triclabendazole into the liver fluke, Fasciola hepatica. Parasitology 136:523-535.
36. Valero, M. A., M. De Renzi, M. Panova, M. A. Garcia-Bodelon, M. V. Periago, D. Ordonez, and S. Mas-Coma. 2006. Crowding effect on adult growth, pre-patent period and egg shedding of Fasciola hepatica. Parasitology 133:453-463.
37. Vennerstrom, J. L., S. Arbe-Barnes, R. Brun, S. A. Charman, F. C. Chiu, J. Chollet, Y. Dong, A. Dorn, D. Hunziker, H. Matile, K. McIntosh, M. Padmanilayam, J. Santo Tomas, C. Scheurer, B. Scorneaux, Y. Tang, H. Urwyler, S. Wittlin, and W. N. Charman. 2004. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430:900-904.
38. Walker, S. M., B. McKinstry, J. C. Boray, G. P. Brennan, A. Trudgett, E. M. Hoey, H. Fletcher, and I. Fairweather. 2004. Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro. Parasitol. Res. 94:427-438.
39. Zhang, Y. 2007. Advances in the treatment of tuberculosis. Clin. Pharmacol. Ther. 82:595-600.